Company news

Royalty Pharma plc news in 2021

Royalty Pharma plc's news releases, calls and decks from 2021, newest first.

View company

Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

November 28, 2021

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

November 21, 2021

Royalty Pharma Reports Third Quarter 2021 Results

November 9, 2021

Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021

October 17, 2021

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

October 14, 2021

Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients

September 8, 2021

Royalty Pharma Reports Second Quarter 2021 Results

August 10, 2021

Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021

July 18, 2021

Royalty Pharma Declares Third-Quarter 2021 Dividend

July 15, 2021

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

July 14, 2021

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

June 1, 2021

Royalty Pharma Reports First Quarter 2021 Results

May 10, 2021

Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021

April 20, 2021

Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes

April 20, 2021

Royalty Pharma Declares Second-Quarter 2021 Dividend

April 14, 2021

Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million

April 7, 2021

Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

April 7, 2021

Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK

March 31, 2021

Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director

March 29, 2021

Royalty Pharma Reports Q4 2020 and Full-Year Results

February 16, 2021

Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021

January 21, 2021

Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences

January 18, 2021

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

January 18, 2021

Royalty Pharma Announces 13% Dividend Increase

January 7, 2021

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12

January 6, 2021

Calls in 2021

Decks in 2021